CRT Capital Starts Ultragenyx Pharma (RARE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jefferies Weighs In on Ultragenyx Pharma (RARE) Related to SIMD Abstracts
March 25, 2015 7:34 AM EDTJefferies analyst Ryan Martins provided his take on SIMD abstracts relevant to Ultragenyx Pharma (NASDAQ: RARE). The firm reiterated a Buy rating and $74 price target.
Martins commented, "RARE will present 12 month data from the eIND patient on rhGUS, where we expect... More
